About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Florida | 10,975 Studies Near You | Clareo Health

Clinical Trials LocationsFlorida

Clinical Trials in Florida

Discover 10,975 clinical trials near Florida. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 10601-10620 of 10,975 trials

TERMINATEDPhase 2/325 miles

A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

NCT00664183

The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.

Diabetic Retinopathy

Vitreoretinal Technologies, Inc.400 participantsStarted Mar 2008

Phoenix, Arizona, United States • Beverly Hills, California, United States • Santa Ana, California, United States +14 more locations

COMPLETEDPhase 341 miles

Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee

NCT00722852

The purpose of this study is to provide replicated evidence of safety and efficacy of 100 mg ketoprofen in Diractin®.

Osteoarthritis of the Knee

IDEA AG555 participantsStarted Jun 2008

Phoenix, Arizona, United States • Tempe, Arizona, United States • Tucson, Arizona, United States +34 more locations

Find Trials by Condition in Florida

Breast Cancerin Florida Lung Cancerin Florida Prostate Cancerin Florida Colorectal Cancerin Florida Melanomain Florida Leukemiain Florida Lymphomain Florida Pancreatic Cancerin Florida Ovarian Cancerin Florida Brain Cancerin Florida Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 341 miles

Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus

NCT00519142

The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which measures improvement in blood sugar after of treatment.

Diabetes Mellitus, Type 2

Elixir Pharmaceuticals367 participantsStarted Aug 2007

Glendale, Arizona, United States • Greenbrae, California, United States • La Jolla, California, United States +58 more locations

COMPLETEDPhase 349 miles

Memory Impairment Study (Mild Cognitive Impairment Study)

NCT00000173

The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.

Alzheimer Disease

National Institute on Aging (NIA)Started Mar 1999

Phoenix, Arizona, United States • Tucson, Arizona, United States • Irvine, California, United States +69 more locations

TERMINATEDPhase 149 miles

TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

NCT00243763

The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).

Multiple Myeloma

Novartis64 participants

Scottsdale, Arizona, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +2 more locations

COMPLETEDPhase 349 miles

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

NCT00618956

The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.

Forest Laboratories321 participantsStarted Oct 2007

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +35 more locations

COMPLETEDPhase 249 miles

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563

The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.

Pfizer450 participantsStarted Mar 2006

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +45 more locations

TERMINATEDPhase 357 miles

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

NCT00141011

The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.

StrokeCerebral IschemiaBrain Infarction

Neurobiological Technologies277 participantsStarted Sep 2005

Phoenix, Arizona, United States • Fort Smith, Arkansas, United States • Loma Linda, California, United States +97 more locations

COMPLETEDPhase 157 miles

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

NCT00768404

VI-0521, a fixed dose combination of immediate-release (IR) phentermine and controlled-release (CR) topiramate, is in Phase III clinical development as a potential therapy for obesity. In human, both phentermine and topiramate are primarily cleared by renal excretion. The contribution of hepatic metabolism to elimination of phentermine and topiramate is not significant. Obese patients, the proposed indicated population for future treatment with VI-0521, are likely to have renal impairment. Therefore, this study is important in understanding the effect of renal impairment on the pharmacokinetics of topiramate and phentermine in subjects with renal impairment compared to subjects with normal renal function.

Renal Impairment

VIVUS LLC32 participantsStarted Oct 2008

Anaheim, California, United States • Miami, Florida, United States • Orlando, Florida, United States +1 more locations

COMPLETEDPhase 157 miles

A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

NCT00768209

This study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment. 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.

Hepatic Impairment

VIVUS LLC18 participantsStarted Oct 2008

Miami, Florida, United States • Orlando, Florida, United States

COMPLETEDPhase 457 miles

A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients

NCT00536471

Study F1J-US-HMFS comprises two identical multicenter, 9-month, randomized, placebo-controlled, double-blind, trials (HMFSa and HMFSb). The purpose of this study is to compare the efficacy and safety of Duloxetine 60 milligrams (mg) once daily to placebo on depression in patients aged 18-65. Data from the two trials will be reported in both individual and pooled analyses. Pooling the two studies will allow for increased power to detect differences between duloxetine and placebo on secondary and exploratory objectives. Only one data lock is planned for this study, when all patients have completed all study procedures.

Major Depressive Disorder

Eli Lilly and Company776 participantsStarted Sep 2007

Beverly Hills, California, United States • Escondido, California, United States • National City, California, United States +44 more locations

COMPLETEDPhase 261 miles

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

NCT00481520

The primary purpose of the study is to assess whether SAM-531, an investigational drug, is safe and well tolerated, compared with placebo (a medically inactive substance), in subjects with mild to moderate Alzheimer's disease.

Alzheimer Disease

Wyeth is now a wholly owned subsidiary of Pfizer72 participantsStarted Jun 2007

Delray Beach, Florida, United States • Hallandale, Florida, United States • St. Petersburg, Florida, United States +4 more locations

COMPLETEDPhase 361 miles

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

NCT00220766

The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at two different infusion rates. The primary objective is to compare the incidence and severity of all infusion related adverse events when IGIV-C, 10% is administered at a rate of 0.14 mL/kg/min compared to a rate of 0.08 mL/kg/min after a single daily infusion.

Immunologic Deficiency SyndromeAgammaglobulinemiaSevere Combined Immunodeficiency+2 more

Grifols Therapeutics LLC100 participantsStarted Aug 2002

Birmingham, Alabama, United States • Denver, Colorado, United States • Washington D.C., District of Columbia, United States +10 more locations

COMPLETEDPhase 368 miles

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

NCT00630877

The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin (ASA) daily for 6 weeks. The FAST is a questionnaire that was developed to provide a detailed assessment of flushing symptoms and their impact in patients receiving niacin therapy. The effect of aspirin on flushing symptoms, as measured by the FAST, was also evaluated.

Abbott276 participantsStarted Feb 2008

Birmingham, Alabama, United States • Anaheim, California, United States • Walnut Creek, California, United States +37 more locations

TERMINATEDPhase 2139 miles

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

NCT00021723

A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.

Alzheimer's Disease

JANSSEN Alzheimer Immunotherapy Research & Development, LLC375 participantsStarted Sep 2001

Peoria, Arizona, United States • Phoenix, Arizona, United States • Beverly Hills, California, United States +8 more locations

COMPLETEDPhase 3152 miles

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

NCT00527514

This study will be conducted to assess the efficacy and safety of an amlodipine/olmesartan treatment regimen in stage 1 and stage 2 hypertensive subjects.

Daiichi Sankyo185 participantsStarted Sep 2007

Buena Park, California, United States • Long Beach, California, United States • Los Angeles, California, United States +15 more locations

COMPLETEDPhase 3166 miles

Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age

NCT00244595

The objectives of this study are to describe candesartan cilexetil antihypertensive effects in terms of achieved blood pressure and hypertension control rates and the relationship between subject characteristics and antihypertensive efficacy, and between antihypertensive therapy (candesartan cilexetil dose and add-on treatments) and efficacy over a 1 year treatment period in hypertensive children ages 6 to \< 17 years; to describe growth in terms of height and weight in the study population; to describe change in neurocognition as assessed by the Full Scaled IQ score in a subset of study subjects; to determine the pharmacokinetics of candesartan in hypertensive paediatric subjects ages 6 to \< 17 years; and to describe safety including adverse events and adverse events necessitating study drug discontinuation including dose level and dose duration relationships and growth over a 1 year period in hypertensive children age 6 to \< 17 years.

AstraZeneca235 participantsStarted Sep 2003

Phoenix, Arizona, United States • Beverly Hills, California, United States • Los Angeles, California, United States +41 more locations

COMPLETEDPhase 3177 miles

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

NCT00494013

The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.

Diabetes Mellitus Type 2

Eli Lilly and Company442 participantsStarted Aug 2007

Hueytown, Alabama, United States • Litchfield Park, Arizona, United States • Phoenix, Arizona, United States +53 more locations

COMPLETEDPhase 4810 miles

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

NCT00418171

The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.

Pfizer18,239 participantsStarted Feb 2002

San Bernardino, California, United States • ‘Aiea, Hawaii, United States • Schaumburg, Illinois, United States +2 more locations

COMPLETEDPhase 4881 miles

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

NCT00090038

The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.

Non-Hodgkin's Lymphoma

Biogen168 participantsStarted Oct 2003

Los Angeles, California, United States • Honolulu, Hawaii, United States • Urbana, Illinois, United States +42 more locations

PreviousPage 531 of 549Next

in Florida

Heart Diseasein Florida